Pentoxifylline is a methylxanthine derivative used to increase blood flow in peripheral atherosclerosis. Pentoxifylline is known to increase whole blood filtration rate, and recent evidence suggests that pentoxifylline increases the filtration rate of polymorphonuclear leukocytes (PMNs). The purpose of this study was to directly observe and quantitate the effect of pentoxifylline on the flow of individual PMNs into a model capillary. Short-term incubation of human PMNs with 10 mM pentoxifylline inhibited cell activation, as judged by a significant reduction in the number of neutrophils forming pseudopods. Furthermore, incubation of PMNs from 6 healthy men with 0.1, 1.0 and 10 mM pentoxifylline significantly decreased the time required for individual cells to be aspirated into a 4 μm pipet under constant pressure by 16 ± 5%, 21 ± 7%, and 41 ± 8%, respectively (mean ± SEM, p≤0.05), compared with control. These experiments are the first direct demonstration of increased deformability in neutrophils treated with pentoxifylline. The results are consistent with the hypothesis that the beneficial effect of pentoxifylline on microvascular perfusion is partly due to an inhibition of PMN stiffness and activation.
Get full access to this article
View all access options for this article.
References
1.
Aviado DM, Porter JM: Pentoxifylline: A new drug for the treatment of intermittent claudication. Mechanism of action, pharmacokinetics, clinical efficacy and adverse effects . Pharmacotherapy4:297-307, 1984.
2.
Ehrly AM: Effects of orally administered pentoxifylline on muscular oxygen pressure in patients with intermittent claudication. IRCS J Med Sci19:401-402, 1982.
3.
Rossner M., Müller R.: On the assessment of the efficacy of pentoxifylline (Trental). J Med18:1-15, 1987.
4.
Porter JM, Cutler BS, Lee BY, et al: Pentoxifylline efficacy in the treatment of intermittent claudication: Multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J104:66-72, 1982.
5.
Schönharting M., Musikié P., and Müller R.: The haemorheological and antithrombotic potential of pentoxifylline ('Trental'): a review. Pharmatherapeutica5:159-169, 1988.
6.
Schmalzer EA , Chien S.: Filterability of leukocytes: Effect of pentoxifylline . Blood64:542-546, 1984.
7.
Matrai A., Ernst E.: Pentoxifylline improves white cell rheology in claudicants. Clin Hemorheology5:483-491, 1985.
8.
Nees S., Schönharting M.: Role of different blood cell types in blood rheology. In: Pentoxifylline and Leukocyte Function, ed. by Mandell Gl, Novick WJ.Somerville, New Jersey: Hoechst-Roussel Pharmaceuticals, Inc, 1987, pp105-114.
9.
English D., Andersen BR: Single-step separation of red blood cells, granulocytes and mononuclear leukocytes on discontinuous density gradients of Ficoll-Hypaque. J Immun Methods5:249-252, 1974.
10.
Sung K-LP , Schmid-Schönbein GW, Skalak R., et al: Influence of physicochemical factors on rheology of human neutrophils. Biophys J39:101-106, 1982.
11.
SAS Institute Inc., Box 8000, Cary, North Carolina 27511-8000.
12.
Statgraphics. STSC, Inc, 2115 East Jefferson Street, Rockville, Maryland 20852.
13.
Reid HL, Barnes AJ, Lock PJ, et al: A simple method for measuring erythrocyte deformability. J Clin Pathol29:855-858, 1976.
14.
Ehrly AM: Improvement of the flow properties of blood. A new therapeutical approach in occlusive arterial disease. Angiology27:188-196, 1976.
15.
Angelkort B. , Maurin N., Boateng K.: Influence of pentoxifylline on erythrocyte deformability in peripheral occlusive arterial disease. Curr Med Res Opin6:255-258, 1979.
16.
Schubotz R. , Mühlfellner O.: The effect of pentoxifylline on erythrocyte deformability and on phosphatide fatty acid distribution in the erythrocyte membrane. Curr Med Res Opin4:609-617, 1977.
17.
Gaillard S. , Schooneman F., Voisin P., et al: Effets comparés sur la filtrabilité in vivo chez l'homme de deux formes galéniques de la pentoxifylline. Ann Méd Nancy18:1099-1102, 1979.
18.
Chien S., Sung K-LP, Schmid-Schönbein GW, et al: Rheology of leukocytes. Ann NY Acad Sci516: 333-347, 1987.
19.
Chien S., Schmalzer EA, Lee Mml, et al: Role of white blood cells in filtration of blood cell suspensions . Biorheology20:11-27, 1983.
20.
Bagge U., Branemark PI: White blood cell rheology: An intravital study in man. Adv Microcirc7:1-17, 1977.
21.
Lichtman MA , Weed RI: Alteration of the cell periphery during granulocyte maturation: Relationship to cell function. Blood39:301-316, 1972.
22.
Miller ME, Myers KA: Cellular deformability of the human peripheral blood polymorphonuclear leukocyte: Method of study, normal variation and effects of physical and chemical alterations. ResJ Reticuloendothel Soc18:337-345, 1975.
23.
Schmid-Schönbein GW, Sung Klp, Tozeren H., et al: Passive mechanical properties of human leukocytes. Biophys J36:243-256, 1981.
24.
Evans EA: Structural model for passive granulocyte behavior based on mechanical deformation and recovery after deformation tests. In: White Cell Mechanics: Basic Science and Clinical Aspects, ed. by Meiselman HJ, Lichtman MA, LaCelle PL.New York: Alan R Liss, Inc, 1984, pp53-71.
25.
Evans EA, Kukan B.: Passive material behavior of granulocytes based on large deformation and recovery after deformation tests. Blood64:1028-1035, 1984.
26.
Engler RL, Schmid-Schönbein GW, Pavelec RS: Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog. Am J Pathol111:98-111, 1983.
27.
Engler RL, Dahlgren MD, Morris DD, et al: Role of leukocytes in response to acute myocardial ischemia and reflow in dogs. Am J Physiol251 (Heart Circ Physiol20):H314-H322, 1986.
28.
Bagge, U., Amundson B., Lauritzen C.: White blood cell deformability and plugging of skeletal muscle capillaries in hemorrhagic shock. Acta Physiol Scand180:159-163, 1980.
29.
Ernst E., Matrai A.: Altered red and white blood cell rheology in type II diabetes. Diabetes35:1412-1415, 1986.
30.
DeVaro J., Chumdermpadetsuk R., Edelman R., et al: Polymorphonuclear (PMN) filterability in diabetes mellitus. Invest Ophthalmol Vis Sci29:181, 1988.
31.
Insel J., Halle AA, Mirvis, DM: Efficacy of pentoxifylline in patients with stable angina pectoris. Angiology39:514-519, 1988.
32.
Hartmann A. , Tsuda Y.: A controlled study on the efficacy of pentoxifylline and an ergot alkaloid derivative on regional cerebral blood flow in patients with chronic cerebrovascular disease. Angiology39:449-457, 1988.
33.
Schultheiss R., Leuwer R., Lenniger-Follert E., et al: Tissue pO2 of human brain cortex—method, basic results and effects of pentoxifylline . Angiology38:221-225, 1987.
34.
Herskovits E., Famulari A., Tamaroff L., et al: Preventive treatment of cerebral transient ischemia: Comparative randomized trial of pentoxifylline versus conventional antiaggregants. Eur Neurol24:73-81, 1985.
35.
Yessenow RS , Maves MD: The effects of pentoxifylline on random skin flap survival. Arch Otolaryngol Head Neck Surg115:179-181, 1989.
36.
Waxman K.: Pentoxifylline and hemorrhagic shock: Experimental studies. In P entoxifylline and Leukocyte Function, ed. by GL Mandell, Novick WJ.Somerville, New Jersey: Hoechst-Roussel Pharmaceuticals, Inc, 1987, pp224-233.
37.
Schade UF, van der Bosch J., Schönharting MM: Increase of survival rate by pentoxifylline in endotoxic shock. In: Pentoxifylline and Leukocyte function, ed. by Mandell GL, Novick WJ.Somerville, New Jersey: Hoechst-Roussel Pharmaceuticals, Inc, 1987, pp 175-183.
38.
Ferrari E., Fioravanti M., Patti AL, et al: Effects of long-term treatment (4 years) with pentoxifylline on haemorheological changes and vascular complications in diabetic patients . Pharmatherapeutica5:26-38, 1987.
39.
Rao Kmk, Crawford J., Currie MS, et al: Actin depolymerization and inhibition of capping induced by pentoxifylline in human lymphocytes and neutrophils. J Cell Physiol137:577-582, 1988.
40.
Bertocchi F., Prosperpio P., Lampugnani MG, et al: The effect of pentoxifylline on polymorphonuclear cell adhesion to cultured endothelial cells. A preliminary report. In Pentoxifylline and Leukocyte Function, ed. by Mandell GL , Novick WJ.Somerville, New Jersey: Hoechst-Roussel Pharmaceuticals, Inc, 1987, pp 68-74.
41.
Bessler H., Gilgal R., Djaldetti M., et al: Effect of pentoxifylline on the phagocytic activity, cAMP levels, and superoxide anion production by monocytes and polymorphonuclear cells. J Leukocyte Biol40:747-754, 1986.
42.
Sullivan GW, Carper HT, Novick WJ, et al: Pentoxifylline inhibits the inflammatory effects of endotoxin and endotoxin induced cytokines on neutrophil function. In: Pentoxifylline and Leukocyte Function, ed. by Mandell GL and Novick WJ.Somerville, New Jersey: Hoechst-Roussel Pharmaceuticals, Inc, 1987, pp 37-48.
